<SEC-DOCUMENT>0001636587-24-000039.txt : 20241114
<SEC-HEADER>0001636587-24-000039.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114120055
ACCESSION NUMBER:		0001636587-24-000039
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20241114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mural Oncology plc
		CENTRAL INDEX KEY:			0001971543
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94252
		FILM NUMBER:		241459110

	BUSINESS ADDRESS:	
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T380
		BUSINESS PHONE:		353 1 905 8020

	MAIL ADDRESS:	
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T380

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mural Oncology Ltd
		DATE OF NAME CHANGE:	20230403

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pistachiovale Ltd
		DATE OF NAME CHANGE:	20230329

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACORN BIOVENTURES, L.P.
		CENTRAL INDEX KEY:			0001766853
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE
		STREET 2:		32ND FL
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		917-940-2732

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE
		STREET 2:		32ND FL
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001636587-24-000029</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001766853</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.01 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>08/09/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001971543</issuerCik>
        <issuerName>Mural Oncology plc</issuerName>
        <issuerCusip>G63365103</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>10 EARLSFORT TERRACE</com:street1>
          <com:street2>10 EARLSFORT TERRACE</com:street2>
          <com:city>DUBLIN 2</com:city>
          <com:stateOrCountry>L2</com:stateOrCountry>
          <com:zipCode>D02 T380</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>ACORN BIOVENTURES, L.P.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>452433.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>452433.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>452433.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>2.7</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>ACORN BIOVENTURES 2, L.P.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>624789.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>624789.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>624789.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>3.7</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>ACORN CAPITAL ADVISORS GP, LLC</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>452433.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>452433.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>452433.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>2.7</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>ACORN CAPITAL ADVISORS GP 2, LLC</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>624789.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>624789.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>624789.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>3.7</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Anders Hove</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1077222.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1077222.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1077222.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>6.3</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Mural Oncology plc</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>10 EARLSFORT TERRACE, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND, D02 T380.</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This statement is filed by:

(i)Acorn Bioventures, L.P. ("Acorn");
(ii)Acorn Capital Advisors GP, LLC ("Acorn GP"), which is the sole general partner of Acorn;
(iii)Acorn Bioventures 2, L.P. ("Acorn 2");
(iv)Acorn Capital Advisors GP 2, LLC ("Acorn GP 2"), which is the sole general partner of Acorn 2; and (v)Anders Hove ("Hove or "Manager").

The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Acorn 2 is a Delaware limited partnership. Acorn GP 2 is a Delaware limited liability company. Anders Hove is a citizen of the United States of America.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>The percentages set forth herein are calculated based upon 17,060,310 Common Stock, nominal value $0.01 per share, outstanding on November 1, 2024 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period as of  September 30, 2024  filed with the Securities and Exchange Commission on November 13, 2024.


</amountBeneficiallyOwned>
        <classPercent>6.3</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Acorn GP is the general partner of Acorn and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn. Acorn GP 2 is the general partner of Acorn 2 and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn 2.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>The Manager, in his capacity as manager of each of Acorn GP and Acorn GP 2, may be deemed to beneficially own the shares beneficially owned by each of Acorn and Acorn.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>ACORN BIOVENTURES, L.P.</reportingPersonName>
      <signatureDetails>
        <signature>Anders Hove</signature>
        <title>Manager</title>
        <date>11/14/2024</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>ACORN BIOVENTURES 2, L.P.</reportingPersonName>
      <signatureDetails>
        <signature>Anders Hove</signature>
        <title>Manager</title>
        <date>11/14/2024</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>ACORN CAPITAL ADVISORS GP, LLC</reportingPersonName>
      <signatureDetails>
        <signature>Anders Hove</signature>
        <title>Manager</title>
        <date>11/14/2024</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>ACORN CAPITAL ADVISORS GP 2, LLC</reportingPersonName>
      <signatureDetails>
        <signature>Anders Hove</signature>
        <title>Manager</title>
        <date>11/14/2024</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Anders Hove</reportingPersonName>
      <signatureDetails>
        <signature>Anders Hove</signature>
        <title>Manager</title>
        <date>11/14/2024</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
